Executive Advisors
Learn More →
Scientific Advisors
Learn More →
Why EMAW is Different
Redefining
eCOA
for Modern Clinical Trials
Modern trials need modern tools. EMAW delivers scientific precision, operational speed, and unified technology where legacy platforms fall short.
Colin Bower
Commercializing technology to improve clinical trials for 15+ years
Stephen Saber
4 successful IT exits in last 10 years
Alison Silva
Co-Founder Synlogic
Founder of 2 biotech companies that have successfully gone public
Dan DeBonis
CO-FOUNDER CONCORDANT RATER SYSTEMS
Developing eCOA for 20+ years
Gordon Kessler
Founder and General Counsel Officer, AiCure
Nearly 20 years’ experience in patent law and USPTO-registered practitioner.
Pat Harrington
Experienced clinician ensuring endpoint integrity
Strategically balancing high-tech with high-touch for validity and reliability .
Building world class
companies
EMAW is backed by a team of renowned experts in neuropsychiatry, AI, and clinical research. Their strategic guidance ensures our platform stays at the forefront of innovation, compliance, and data integrity in clinical trials.
Our Scientific Founders
Advisor
Dr. Charles Nemeroff
Leadership Experience:
Dr. Charles Nemeroff serves as the Chair and Professor in the Department of Psychiatry and Behavioral Sciences at Dell Medical School, University of Texas. With a distinguished career in psychiatry, he is also the Co-director of the Center for Psychedelic Research and Therapy, where he contributes to groundbreaking studies on mental health treatments. His leadership and expertise play a crucial role in advancing research and clinical practices in psychiatry, particularly in exploring innovative therapeutic approaches.
Advisor
Philip Harvey, MD
Leadership Experience:
Dr. Harvey is a Scientific Officer and serves as the Leonard M. Miller Professor of Psychiatry and Director of the Division of Psychology at the University of Miami Miller School of Medicine. He also serves as a Senior Research Health Scientist at the Department of Veterans Affairs
Academic Positions:
Since joining the University of Miami in July 2010, he has been a prominent figure in psychiatry and behavioral sciences, advancing research and education at the Miller School of Medicine. Honors and Awards: Dr. Harvey has received prestigious accolades, such as the Inaugural Schizophrenia International Research Society Clinical Scientist Distinguished Contributions Award (2012), the John Blair Barnwell Award for Clinical Research from the U.S. Department of Veterans Affairs (2014), and the Stanley Dean Award for Schizophrenia Research (2021).
Research Contributions:
His research focuses on cognition and everyday functioning in schizophrenia and aging, with notable work on cognitive-enhancing interventions and functional skills training.
Our Executive Advisors
Advisor
Stephen Brannan, MD
Leadership Experience
Dr. Brannan most recently served as Chief Medical Officer at Karuna Therapeutics, leading the approval of Cobenfy for treatment of schizophrenia. Karuna was acquired by Bristol Myers Squibb for $14 billion. Previously, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals.
Industry Expertise:
Dr Brannan is a renowned expert in neuroscience drug development, with over 20 years of experience designing and implementing clinical programs for psychiatric and neurological disorders. He has played a pivotal role in advancing the field of neuropsychopharmacology.
Advisor
Raymond Sanchez , MD
Leadership Experience
Dr. Sanchez, as Chief Medical Officer at Cerevel Therapeutics, led the global development of innovative CNS treatments, driving the company’s $8.7 billion acquisition by AbbVie. He is now a Senior Advisor at Bain Capital Life Sciences and serves on the board of directors to many organizations including Rapport Therapeutics and Tenacia Biotechnology. Previously, Dr. Sanchez was the Senior Vice President of Global Clinical Development at Otsuka Pharmaceutical Development and Commercialization.
Industry Expertise:
With more than 20 years of psychiatric, medical, and pharmaceutical industry experience, Dr. Sanchez’s expertise spans across a wide range of therapeutic areas, including sleep disorders, pain management, and psychiatric conditions, where he has driven significant advancements in both traditional and digital health approaches.
Advisor
Andrew J. Cutler, MD
Leadership Experience
Dr. Andrew J. Cutler is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and serves as the Chief Medical Officer of the Neuroscience Education Institute. Previously, he was an Assistant Professor of Psychiatry at the University of Chicago and later founded the Florida Clinical Research Center (FCRC), which he led until its acquisition by Meridien Research. He subsequently served as Executive Vice President and Chief Medical Officer at Meridien until his retirement in 2019.
Industry Expertise:
Dr. Cutler has over 30 years of experience in clinical research, with a focus on central nervous system disorders such as ADHD, Bipolar Disorder, Depression, and Schizophrenia across pediatric and adult populations. He has served as Principal Investigator on more than 400 clinical trials and authored over 150 peer-reviewed publications. Dr. Cutler is board certified in both Internal Medicine and Psychiatry and is a Certified Physician Investigator (CPI). He continues to consult extensively with pharmaceutical and biotechnology companies and serves on the board of the Neuroscience Education Institute.
Advisor
Alex Tkachenko
Over 20 years of experience in biopharmaceutical R&D, leadership and investing
Advisor
Matt Leoni, MD, MBA
Leadership Experience
Dr. Leoni served as the Senior Vice President of Global Clinical Development & Biometrics at Cerevel Therapeutics, driving the company’s $8.7 billion acquisition by AbbVie. In addition, Dr. Leoni served as the Senior Director of Global Clinical Development at Otsuka Pharmaceutical Companies. He is now the Chief Medical Officer at A Third Rock Ventures Company.
Industry Expertise:
With more than 15 years of experience, Dr. Leoni has extensive experience in the pharmaceutical and biotechnology industries, particularly in the areas of clinical development and biometrics. His expertise spans across a range of therapeutic areas, with a particular focus on central nervous system disorders.
Our Scientific Advisors
Advisor
Alan Schatzberg , MD
Leadership Experience:
Dr. Schatzberg served as the President of the American Psychiatric Association and President of the American College of Neuropsychopharmacology.
Academic Positions:
Dr. Schatzberg has been the Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences at Stanford University since 1991. He served as Chair of the Department from 1991 to 2010 and is currently the Director of the Stanford Mood Disorders Center.
Honors and Awards:
He has received numerous accolades, including the Mood Disorders Research Award and the Distinguished Service in Psychiatry Award, both from the American Psychiatric Association.
Research Contributions:
He has authored over 700 publications and abstracts, including the "Manual of Clinical Psychopharmacology."
Advisor
Ned Kalin, MD
Leadership Experience
Dr. Kalin serves as Editor-in-Chief of the American Journal of Psychiatry. He is also the director of the HealthEmotions Research Institute and the Lane Neuroimaging Laboratory.
Academic Positions:
He is the Hedberg Professor and Chair of the Department of Psychiatry at the University of Wisconsin School of Medicine and Public Health.
Honors and Awards:
He has received numerous awards, including the Anna-Monika Prize from the European College of Neuropsychopharmacology and election to the National Academy of Medicine.
Research Contributions:
Dr. Kalin has published over 250 peer-reviewed articles related to the adaptive and maladaptive expression of emotion and anxiety.
Advisor
Sanjay Mathew, MD
Leadership Experience:
Dr. Mathew is the President-Elect and Chief Medical Officer of the Anxiety and Depression Association of America (ADAA). He is also a Board Member of the American Society of Clinical Psychopharmacology and a Fellow of the American College of Neuropsychopharmacology.
Academic Positions:
Dr. Mathew serves as the Vice Chair for Research and a Professor in the Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine. He also directs the Mood and Anxiety Disorders Research Program.
Honors and Awards:
He was named a Clarivate Highly Cited Researcher for 2010-2020 and has been selected by his peers as “Best Doctor” every year since 2011. Research Contributions: His research emphasizes the potential of rapid-acting glutamate-modulating agents, and he has authored over 180 manuscripts and book chapters in this field.